Beyond Air Management

Management criteria checks 3/4

Beyond Air's CEO is Steve Lisi, appointed in Jun 2017, has a tenure of 7.42 years. total yearly compensation is $1.73M, comprised of 37.5% salary and 62.5% bonuses, including company stock and options. directly owns 3.25% of the company’s shares, worth €903.26K. The average tenure of the management team and the board of directors is 2.8 years and 6.8 years respectively.

Key information

Steve Lisi

Chief executive officer

US$1.7m

Total compensation

CEO salary percentage	37.5%
CEO tenure	7yrs
CEO ownership	3.2%
Management average tenure	2.8yrs
Board average tenure	6.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Steve Lisi's remuneration changed compared to Beyond Air's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	US$2m	US$650k	-US$60m
Dec 31 2023	n/a	n/a	-US$67m
Sep 30 2023	n/a	n/a	-US$63m
Jun 30 2023	n/a	n/a	-US$59m
Mar 31 2023	US$9m	US$650k	-US$56m
Dec 31 2022	n/a	n/a	-US$56m
Sep 30 2022	n/a	n/a	-US$51m
Jun 30 2022	n/a	n/a	-US$47m
Mar 31 2022	US$6m	US$450k	-US$43m
Dec 31 2021	n/a	n/a	-US$28m
Sep 30 2021	n/a	n/a	-US$26m
Jun 30 2021	n/a	n/a	-US$23m
Mar 31 2021	US$2m	US$450k	-US$23m
Dec 31 2020	n/a	n/a	-US$23m
Sep 30 2020	n/a	n/a	-US$22m
Jun 30 2020	n/a	n/a	-US$21m
Mar 31 2020	US$1m	US$450k	-US$20m
Dec 31 2019	n/a	n/a	-US$15m
Sep 30 2019	n/a	n/a	-US$13m
Jun 30 2019	n/a	n/a	-US$11m
Mar 31 2019	US$3m	US$450k	-US$7m
Dec 31 2018	n/a	n/a	-US$5m
Sep 30 2018	n/a	n/a	-US$5m
Jun 30 2018	n/a	n/a	-US$10m
Mar 31 2018	US$537k	US$130k	-US$11m
Dec 31 2017	US$2m	US$163k	-US$18m

Compensation vs Market: Steve's total compensation ($USD1.73M) is above average for companies of similar size in the German market ($USD434.04K).

Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.

CEO

Steve Lisi (53 yo)

7yrs

Tenure

US$1,733,000

Compensation

Mr. Steven Adam Lisi, also known as Steve, has been the Chief Executive Officer of Beyond Air, Inc. (formerly known as AIT Therapeutics, Inc.) since June 14, 2017. Mr. Lisi serves as Chief Executive Office...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Steven Lisi	CEO & Chairman of the Board	7yrs	US$1.73m	3.25% $ 903.3k
Amir Avniel	Co-Founder	13.4yrs	US$952.00k	0.95% $ 265.4k
Michael Gaul	Chief Operating Officer	1.9yrs	US$799.00k	0.14% $ 39.5k
Douglas Larson	CFO, Principal Financial Officer & Principal Accounting Officer	2.8yrs	US$1.13m	0.040% $ 11.2k
Edward Barger	Head of Investor Relations	no data	no data	no data
Kori-Ann Taylor	Head of Marketing	3.1yrs	no data	no data
Andrew Colin	Senior Medical Director Global Clinical Leadership & Member of Scientific Advisory Board	2.5yrs	no data	no data
Jeff Myers	Chief Medical Officer	1.3yrs	no data	0.10% $ 28.2k
Adam Newman	Corporate Secretary	no data	US$643.57k	no data

2.8yrs

Average Tenure

53yo

Average Age

Experienced Management: 48L's management team is considered experienced (2.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Steven Lisi	CEO & Chairman of the Board	7.4yrs	US$1.73m	3.25% $ 903.3k
Amir Avniel	Co-Founder	13.4yrs	US$952.00k	0.95% $ 265.4k
Andrew Colin	Senior Medical Director Global Clinical Leadership & Member of Scientific Advisory Board	11.4yrs	no data	no data
Yoori Lee	Independent Director	6.4yrs	US$51.30k	0.028% $ 7.7k
Robert Carey	Independent Director	5.3yrs	US$102.60k	6.49% $ 1.8m
Ron Bentsur	Independent Director	7.4yrs	US$51.30k	0.32% $ 87.7k
William Forbes	Independent Director	5.8yrs	US$51.30k	0.032% $ 9.0k
Yossef Av-Gay	Member of Scientific Advisory Board	6.4yrs	US$75.00k	no data
David Greenberg	Member of Scientific Advisory Board	no data	no data	no data
Richard Malley	Member of Scientific Advisory Board	no data	no data	no data
Erick Lucera	Independent Director	6.8yrs	US$51.30k	0.0095% $ 2.6k
Hannah Blau	Member of Scientific Advisory Board	no data	no data	no data

6.8yrs

Average Tenure

58yo

Average Age

Experienced Board: 48L's board of directors are considered experienced (6.8 years average tenure).

Beyond Air Management

Management criteria checks 3/4

Key information

Recent management updates

Beyond Air Appoints David Webster as Chief Commercial Officer, Effective from July 8, 2024

Beyond Air, Inc., Annual General Meeting, Mar 08, 2024

Independent Director recently bought €1.8m worth of stock

Independent Director recently bought €224k worth of stock

Independent Director recently bought €117k worth of stock

CEO & Chairman of the Board recently bought €61k worth of stock

Recent updates

New major risk - Financial position

Beyond Air, Inc. Updates Revenue Guidance for the Fiscal Year 2025

Beyond Air Appoints David Webster as Chief Commercial Officer, Effective from July 8, 2024

Beyond Air, Inc. to Report Q4, 2024 Results on Jun 24, 2024

Beyond Air, Inc. has completed a Follow-on Equity Offering in the amount of $16.000003 million.

Beyond Air, Inc. has filed a Follow-on Equity Offering in the amount of $16.000003 million.

New major risk - Financial position

Beyond Air, Inc. has filed a Follow-on Equity Offering.

New major risk - Revenue and earnings growth

Beyond Air, Inc., Annual General Meeting, Mar 08, 2024

Beyond Air, Inc. to Report Q3, 2024 Results on Feb 12, 2024

Independent Director recently bought €1.8m worth of stock

New major risk - Financial position

Beyond Air, Inc. to Report Q2, 2024 Results on Nov 13, 2023

Beyond Air, Inc. Announces Publication of Positive New Preclinical Data for the Treatment of Autism Spectrum Disorder

Independent Director recently bought €224k worth of stock

New minor risk - Market cap size

New major risk - Share price stability

No longer forecast to breakeven

Beyond Air, Inc. to Report Q1, 2024 Results on Aug 10, 2023

New major risk - Revenue and earnings growth

New minor risk - Shareholder dilution

No longer forecast to breakeven

Beyond Air, Inc. announced that it expects to receive $40 million in funding

Beyond Air, Inc. to Report Q4, 2023 Results on Jun 22, 2023

Forecast to breakeven in 2026

Forecast to breakeven in 2026

Independent Director recently bought €117k worth of stock

Forecast to breakeven in 2026

CEO & Chairman of the Board recently bought €61k worth of stock

Independent Director recently bought €56k worth of stock

Beyond Air, Inc., Annual General Meeting, Mar 09, 2023

Beyond Air, Inc. to Report Q3, 2023 Results on Feb 09, 2023

Independent Director recently bought €110k worth of stock

Independent Director recently bought €167k worth of stock

Independent Director recently bought €284k worth of stock

No longer forecast to breakeven

Insufficient new directors

No longer forecast to breakeven

Beyond Air® Announces Positive Data for Inhaled Nitric Oxide (NO) to Treat COVOD-19 with LungFit® PRO in A Poster Presentation At IDWeek 2022

Beyond Air, Inc. to Report Q2, 2023 Results on Nov 08, 2022

Beyond Air, Inc. Announces Positive Data from At-Home Pilot Study in Patients with Refractory NTM Lung Infection Treated with (NO) Using the LungFit® GO at the CHEST Annual Meeting 2022

Beyond Air Announces Annals of the American Thoracic Society Published Review of the Third Pilot Study of High Dose Nitric Oxide for Bronchiolitis

Beyond Air, Inc. to Report Q1, 2023 Results on Aug 11, 2022

Beyond Air, Inc. Appoints Michael Gaul as Chief Operating Officer

Independent Director recently bought €1.1m worth of stock

Beyond Air, Inc. Announces Executive Changes

No longer forecast to breakeven

Full year 2022 earnings released: US$1.68 loss per share (vs US$1.27 loss in FY 2021)

Beyond Air’s LungFit PH Receives FDA Approval to Treat Term and Near-Term Neonates with Hypoxic Respiratory Failure

Beyond Air® Presents Positive Study Update from the At-Home LungFit® GO Pilot Study for Nontuberculous Mycobacterial Lung Disease at the American Thoracic Society International Conference 2022

Beyond Air, Inc. to Report Q4, 2022 Results on Jun 16, 2022

Insufficient new directors

Beyond Air, Inc. Reports Positive Long-Term Safety Data for High Concentration Inhaled Nitric Oxide in Bronchiolitis at the Pediatric Academic Societies Meeting 2022

Independent Director recently bought €123k worth of stock

Insufficient new directors

Independent Director recently bought €158k worth of stock

Independent Director recently bought €121k worth of stock

Insufficient new directors

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Beyond Air, Inc. to Report Q3, 2022 Results on Feb 10, 2022

Independent Director recently bought €84k worth of stock

CEO & Chairman of the Board recently bought €302k worth of stock

Beyond Air, Inc Provides Regulatory Update for LungFit® PH

Co-Founder recently sold €396k worth of stock

Independent Director recently bought €149k worth of stock

First half 2022 earnings released

Beyond Air® Provides Global Regulatory Update for Lungfit® Ph

CEO & Chairman of the Board recently bought €166k worth of stock